Cytokinetics

Resilience in the Fight Against ALS (eBook, ePUB)

• Format: ePub

Produktbeschreibung

For over a decade, Cytokinetics, a biopharmaceutical company, has been at the forefront of the fight to discover new potential therapies for people living with ALS. Ultimately, the company was unsuccessful in bringing forward a new medicine for people with ALS, and while some might see this as a story ending in failure, it is anything but. This book shares the company's journeyinspired and guided by the extraordinary members of the greater ALS community.

That journey began with an innovative idea: What if a therapy could focus on muscle function, not just on neurons? The company used their expertise in the mechanics of muscle to investigate this novel approach, giving rise to the discovery and development of two investigational medicines. Many people with ALSin a heroic show of grace, strength, and braverylent their advice and volunteered to participate in clinical trials. While a cure for ALS and other neuromuscular diseases still remains, sadly, out of reach, the connection between company and community endures.

This book shares the experience and learnings that Cytokinetics gained, and serves as a way to pass the baton to other members of the industry and the scientific community who are dedicated to bringing forward new therapies in the hopes that it will honor all those who participated and shine a light on the path forward.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.

Produktdetails

• Verlag: Melcher Media Inc
• Erscheinungstermin: 7. Mai 2024
• Englisch
• ISBN-13: 9781595911421
• Artikelnr.: 70611648

Autorenporträt

Cytokinetics is a South San Franciscobased late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. Since the company's founding more than 25 years ago, Cytokinetics has built a robust pipeline of therapies with promise for people living with diseases characterized by muscle weakness, loss, and dysfunction. Cytokinetics is driven by a longstanding commitment to patients and caregivers, and it is dedicated to keeping them at the center of their work. The company was unsuccessful in bringing forward a new medicine for people with ALS but is passionate about sharing the journey of discovery and development with the community they served for more than a decade. Cytokinetics hopes that their experience may educate, inform, and inspire future research and development.